Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois?

S. Savastano, N. Balato, F. Gaudiello, C. Di Somma, V. Brancato, A. Colao, F. Ayala, Giovanni Tarantino

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalEuropean Journal of Inflammation
Volume9
Issue number3
Publication statusPublished - Sep 2011

Fingerprint

Somatomedins
Insulin-Like Growth Factor I
Psoriasis
Inflammation
Metabolic Diseases
Adiposity
Insulin Resistance
Cardiovascular Diseases
C-Reactive Protein
Fibrinogen
HDL Cholesterol
Interleukin-6
Homeostasis
Cholesterol
Education
Population

Keywords

  • IGF-I
  • Inflammation
  • Metabolic syndrome
  • Psoriasis
  • Visceral adiposity index

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Savastano, S., Balato, N., Gaudiello, F., Di Somma, C., Brancato, V., Colao, A., ... Tarantino, G. (2011). Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois? European Journal of Inflammation, 9(3), 277-283.

Insulin-like growth factor-1, psoriasis, and inflammation : A ménage à trois? / Savastano, S.; Balato, N.; Gaudiello, F.; Di Somma, C.; Brancato, V.; Colao, A.; Ayala, F.; Tarantino, Giovanni.

In: European Journal of Inflammation, Vol. 9, No. 3, 09.2011, p. 277-283.

Research output: Contribution to journalArticle

Savastano, S, Balato, N, Gaudiello, F, Di Somma, C, Brancato, V, Colao, A, Ayala, F & Tarantino, G 2011, 'Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois?', European Journal of Inflammation, vol. 9, no. 3, pp. 277-283.
Savastano S, Balato N, Gaudiello F, Di Somma C, Brancato V, Colao A et al. Insulin-like growth factor-1, psoriasis, and inflammation: A ménage à trois? European Journal of Inflammation. 2011 Sep;9(3):277-283.
Savastano, S. ; Balato, N. ; Gaudiello, F. ; Di Somma, C. ; Brancato, V. ; Colao, A. ; Ayala, F. ; Tarantino, Giovanni. / Insulin-like growth factor-1, psoriasis, and inflammation : A ménage à trois?. In: European Journal of Inflammation. 2011 ; Vol. 9, No. 3. pp. 277-283.
@article{eb71dab537414de8a0cea63b4c70ffe1,
title = "Insulin-like growth factor-1, psoriasis, and inflammation: A m{\'e}nage {\`a} trois?",
abstract = "Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p",
keywords = "IGF-I, Inflammation, Metabolic syndrome, Psoriasis, Visceral adiposity index",
author = "S. Savastano and N. Balato and F. Gaudiello and {Di Somma}, C. and V. Brancato and A. Colao and F. Ayala and Giovanni Tarantino",
year = "2011",
month = "9",
language = "English",
volume = "9",
pages = "277--283",
journal = "European Journal of Inflammation",
issn = "1721-727X",
publisher = "Biolife",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor-1, psoriasis, and inflammation

T2 - A ménage à trois?

AU - Savastano, S.

AU - Balato, N.

AU - Gaudiello, F.

AU - Di Somma, C.

AU - Brancato, V.

AU - Colao, A.

AU - Ayala, F.

AU - Tarantino, Giovanni

PY - 2011/9

Y1 - 2011/9

N2 - Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p

AB - Psoriatic patients have an accumulation of metabolic syndrome (MS) and cardiovascular diseases (CVD), likely mediated by systemic inflammation, and exhibiting low circulating levels of insulin-like growth factor (IGF)-I, a marker of MS and CVD in the general population. The aim of this study is to determine the association of IGF-I and inflammation, and to assess the cardio-metabolic risk calculating the visceral adiposity index (VAI), in a group of psoriatic patients without MS. IGF-I, fibrinogen, C-reactive protein (CRP), and interleukin (IL)-6 levels were determined in 20 patients with moderate to severe psoriasis (age range 23-77 yrs) without MS, according to criteria of the National Cholesterol Education Program's Adult Panel III (ATP III), and 20 age- and BMI-matched controls. The standard deviation score (SDS) of IGF-I levels according to age (zSDS), the homeostasis model assessment of insulin resistance (HOMA-IR), the whole-body insulin sensitivity index (ISI), and VAI were also calculated. Psoriasis Area and Severity Index (PASI) mean value was 17.8±11. HDL cholesterol and IGF-I zSDS values were lower (p

KW - IGF-I

KW - Inflammation

KW - Metabolic syndrome

KW - Psoriasis

KW - Visceral adiposity index

UR - http://www.scopus.com/inward/record.url?scp=84858691206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858691206&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84858691206

VL - 9

SP - 277

EP - 283

JO - European Journal of Inflammation

JF - European Journal of Inflammation

SN - 1721-727X

IS - 3

ER -